D2清扫改善晚期胃癌疾病特异性生存:意大利胃癌研究组D1对比D2随机对照试验15年随访结果
意大利胃癌研究组在5个中心开展随机对照试验,1998至2006年纳入267例胃癌患者,随机接受D1或D2胃切除术,中位随访16.76年。全体人群中D1与D2的总生存和疾病特异性生存无差异,但在pT>1N+的晚期患者中D2的疾病特异性生存显著更高;>70岁患者和早期患者中D1的生存更优。
要点
- 全体人群中D1与D2的总生存和疾病特异性生存无显著差异。
- pT>1N+晚期患者中D2的疾病特异性生存显著优于D1。
- >70岁患者和早期患者中D1的总生存和疾病特异性生存更优。
核心结论
- 全体人群随访15年后D1与D2的总生存和疾病特异性生存无相关差异。
- 在pT>1N+的晚期伴淋巴结转移患者中,D2清扫可改善疾病特异性生存和胃癌相关死亡率。
- 研究提示老年患者和早期病变患者应优先选择D1手术,而晚期病例在转诊中心经充分术前评估后可推荐D2手术。
研究设计与样本
- 术中通过电话由中心随机分配至D1或D2胃切除术,共267例合格患者,D1组133例、D2组134例。
- 主要终点为总生存,次要终点为疾病特异性生存、术后并发症和死亡率,分析按意向性治疗进行。
- 对手术、淋巴结清扫、病理和患者随访实施严格质量控制并监测,注册号为ISRCTN11154654。
主要发现
- 全体人群中D1与D2的总生存分别为51.3%和46.8%(p=0.31),疾病特异性生存分别为65%和67%(p=0.94),均无显著差异。
- pT>1N+患者中D2的疾病特异性生存显著高于D1(29.4% vs. 51.4%,p=0.035)。
- >70岁患者中D1的总生存和疾病特异性生存更优(p=0.003和p=0.006)。
- 早期患者中D1的疾病特异性生存更高(p=0.01)。
临床怎么用
- 对pT>1N+的晚期伴淋巴结转移胃癌患者,可考虑推荐D2淋巴结清扫以改善疾病特异性生存。
- 对>70岁老年患者和早期病变患者,应优先选择D1手术。
- 在转诊中心通过充分的术前评估准确识别晚期病例后,可推荐D2手术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The extended lymphadenectomy (D2) was recently introduced in several guidelines as the optimal treatment for gastric cancer, based only on the 15-year follow-up results of the Dutch randomised trial, while the British Medical Research Council (MRC) study failed to demonstrate a survival benefit over the more limited D1 dissection. The Italian Gastric Cancer Study Group randomised controlled trial (RCT) was also undertaken to compare D1 versus D2 gastrectomy, and a tendency to improve survival in patients with advanced resectable disease (pT > 1N+) was documented despite negative results in the entire patient population. Now we present the 15-year follow-up results of survival and gastric cancer-related mortality. METHODS: Between June 1998 and December 2006, eligible patients with gastric cancer who signed the informed consent were randomised at 5 centres to either D1 or D2 gastrectomy. Intraoperative randomisation was implemented centrally by phone call. Primary outcome was overall survival (OS); secondary end-points were disease-specific survival, postoperative morbidity and mortality. Analyses were by intention to treat. Strict quality control measures for surgery, lymph node removal, pathology and patient follow-up were implemented and monitored. Registration number: ISRCTN11154654 (http://www.controlled-trials.com). FINDINGS: A total of 267 eligible patients were assigned to either D1 (133 patients) or D2 (134) procedure. Median follow-up time was 16.76 years. Analyses were done both in overall patient population and in pT > 1N+. One hundred patients (38.5) were alive without recurrence. OS and disease-specific survival (DSS) were very high in both arms. In overall population, they were not different between D1 and D2 arm (51.3% vs. 46.8% and 65% vs. 67% respectively, p = 0.31 and p = 0.94). DSS was significantly higher after D2 in pT > 1N+ patients (29.4% vs. 51.4%, p = 0.035). OS and DSS were better after D1 in patients older than 70 years (p = 0.003 and p = 0.006). DSS was higher after D1 also in early stages (p = 0.01). INTERPRETATION: After 15-year follow up, despite no relevant difference in overall population, DSS and gastric cancer-related mortality of patients with advanced disease and lymph node metastases are improved by D2 procedure. Further data available from this trial suggest that D1 procedure should be preferably used in older patients and in early disease. As accurate detection of advanced diseases can be currently provided by adequate preoperative workup in referral centres, D2 procedure should be recommended in these cases. FUNDING: Piedmont Regional fund for Finalized Healthy Research Project, Application 2003 for data collection.
引用
- Degiuli M, Reddavid R, Tomatis M, et al. D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian Gastric Cancer Study Group D1 versus D2 randomised controlled trial. Eur J Cancer. 2021. PMID: 33887514. doi:10.1016/j.ejca.2021.03.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。